IRVINE, Calif.--(EON: Enhanced Online News)--Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 1:40 p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
The presentation will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/. A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily intraocular pressure lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA filing for Rhopressa™ (netarsudil ophthalmic solution) 0.02% was resubmitted to the FDA in February 2017. Aerie's second product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, is a fixed dose combination of Rhopressa™ and latanoprost, a widely prescribed prostaglandin analogue. Roclatan™ currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, an NDA for Roclatan™ is expected to be filed in late 2017 or early 2018. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.